Zamanian Abbas, Mobasher Pezhman, Jazi Ghazaleh Ahmadi
Skin and Stem Cell Research Center, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran, Department of Dermatology, Rasoul-e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran, Skin and Stem Cell Research Center, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran.
Adv Biomed Res. 2014 Mar 31;3:107. doi: 10.4103/2277-9175.129701. eCollection 2014.
In the previous studies, it has been shown that mumps-measles-rubella (MMR) vaccine resulted in regression of warts via immunomodulatory effect and induction of immune system. Due to the high prevalence of warts in various populations, we evaluated the efficacy of MMR vaccine injection in the treatment of cutaneous warts.
This double-blind randomized controlled clinical trial was conducted in Hazrat-e-Rasoul Hospital in Tehran in 2011-2012 on 24 patients with warts who were allocated to two groups including MMR group and normal saline group. MMR vaccine was injected intralesionally in the MMR group, whereas normal saline was injected into the lesions in the second group. These injections were repeated every 2 weeks intervals for maximum 3 injections. All patients were followed up every 15-day interval up to 45 days and then up to 6 months regarding relapses and finally, side effects, probable relapse, and therapeutic outcomes were evaluated and compared.
At the end of follow-up period, therapeutic outcomes in the MMR group included no cure in 2 cases, relative cure in 4 cases, and complete cure in 18 cases. In normal saline group, these rates included no cure in seven cases, relative cure in nine cases, and complete cure in six cases (P < 0.001). No significant complication occurred in the two groups.
MMR vaccine may result in desirable therapeutic response. The hypothesis that is considered here is that MMR vaccine, via induction of cellular and humoral immune system, accelerates the destruction of virus and infected host cells.
在先前的研究中，已表明麻腮风（MMR）疫苗通过免疫调节作用和诱导免疫系统，使疣消退。由于疣在不同人群中的高患病率，我们评估了注射MMR疫苗治疗皮肤疣的疗效。
这项双盲随机对照临床试验于2011 - 2012年在德黑兰的哈兹拉特 - 拉苏尔医院对24例疣患者进行，这些患者被分为两组，即MMR组和生理盐水组。MMR组在皮损内注射MMR疫苗，而第二组在皮损内注射生理盐水。每隔2周重复注射，最多注射3次。所有患者每隔15天随访一次，直至45天，然后随访至6个月观察复发情况，最后评估并比较副作用、可能的复发情况和治疗结果。
随访期结束时，MMR组的治疗结果为2例未治愈，4例相对治愈，18例完全治愈。生理盐水组的这些比例为7例未治愈，9例相对治愈，6例完全治愈（P < 0.001）。两组均未发生明显并发症。
MMR疫苗可能产生理想的治疗反应。这里所考虑的假设是，MMR疫苗通过诱导细胞免疫和体液免疫系统，加速病毒及受感染宿主细胞的破坏。
